Fibrocell Science Inc

Fibrocell Science — Investor Day (September 2014)

112 slides from Fibrocell Science's investor day presentation, Sep 24, 2014

  1. Slide 1: Welcome to Fibrocell Science R&D Day

    Welcome to Fibrocell Science R&D Day September 24, 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-

  3. Slide 3: David Pernock, Chairman and CEO

    David Pernock Chairman and CEO Fibrocell Science

  4. Slide 4: Agenda

    Agenda 8:00 am Welcome & Introductions—David Pernock, Chairman & CEO, Fibrocell Science 8:10 am The Power of Fibroblasts—John Maslowski, Vice President, Scientific Affairs, Fibrocell Science 8:25 am Intrexon and Fibrocell Science Collaboration—Working Together to Treat RDEB—Suma Krishnan, Senior Vic

  5. Slide 5: The Power of Fibroblasts

    The Power of Fibroblasts John Maslowski Vice President, Scientific Affairs Fibrocell Science

  6. Slide 6: Fibroblast Cells

    Most common cells in connective tissue Produces ECM proteins, collagenases and plays role in wound healing Readily accessible from skin sample Well-documented culture techniques Development of therapies where fibroblasts are prevalent Fibroblast Cells 6 Scientific precedence for use in gene transfer

  7. Slide 7: Harvesting Fibroblasts

    Harvesting Fibroblasts Ubiquitous in the dermal layer of skin (and underlying layers of other tissues) Accessible by punch biopsy in comparison to highly invasive extraction methods Outpatient procedure Biopsy technique is important for culture success

  8. Slide 8: Culturing Fibroblasts

    Culturing Fibroblasts Adherent cells in culture Does not require highly complex media formulation Expands in both 2D and 3D culture Highly competitive against other skin cell types in culture Purified culture after minimal passaging Harvest hundreds of millions of cells Stable under cryopreservation

  9. Slide 9: Meeting Regulatory Requirements

    Meeting Regulatory Requirements Regulated as a biologic High bar for quality and control Strict tracking controls Extensive testing requirements for safety, viability, identity and potency Achieved BLA approval in June 2011

  10. Slide 10: Two Product Engines – Multiple Therapeutics in Development

    Protein Expression Product Engine Azficel-T Product Engine Two Product Engines – Multiple Therapeutics in Development Collection Culture Administration Vector Preparation Gene Packaging Gene Integration Fibrocell Proprietary Personalized Biologics Approach 10

  11. Slide 11: Creating a Gene Product

    Creating a Gene Product Transfection is the process of deliberately introducing nucleic acids into cells Delivered into the cell using a vector, or a vehicle to artificially carry foreign genetic material into another cell Transduction is often used to describe virus-mediated DNA transfer Our goal:

  12. Slide 12: Gene Therapy Development

    Receptor binding TARGET CELL VIRAL VECTOR Host Cell Genome Protein of Interest PACKAGING CELL Autologous human dermal fibroblast as a vehicle COL7A1 gene construct Viral vector Cell expansion closely mimics our established process with viral transduction step added Additional assays for safety and e

  13. Slide 13: Orphan Indication Prioritization

    Orphan Indication Prioritization RDEB Linear Scleroderma Problem/Solution Well Defined Unmet Need Big Impact/Excellent Value Proposition Localized Approach Fibroblast Ideal Delivery Vehicle Technically Feasible Animal Model ü ü ü ü ü ü ü ü ü ü ü ü ü ü Evaluation Category RDEB Linear Scleroderma 13 h

  14. Slide 14: Benefits of the Fibroblast Cell Platform

    Benefits of the Fibroblast Cell Platform Plays a significant role in the basic biology of skin and other connective tissues Allows for the targeting of biological solutions for conditions of the skin and other connective tissues Autologous nature reduces rejection and immunogenicity risks Local deli

  15. Slide 15: Suma Krishnan, Intrexon Corporation

    15 Suma Krishnan Senior Vice President, Product Development Intrexon Corporation

  16. Slide 16: Intrexon and Fibrocell Collaboration: Working Together to Treat RDEB

    Intrexon and Fibrocell Collaboration: Working Together to Treat RDEB Suma Krishnan Sr. Vice President, Product Development Fibrocell Science R&D Day Yale Club, New York September 24, 2014

  17. Slide 17: Forward-Looking Statements

    Forward-Looking Statements Special Note Regarding Forward-Looking Statements Some of the matters discussed in this presentation may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statem

  18. Slide 18: Intrexon Technology Overview

    Intrexon Technology Overview

  19. Slide 19: Key Characteristics of Our Platform

    Human Animal Plant Our platform is host neutral enabling product development across different cell types with a broad spectrum of end markets Continuously acquire knowledge about biological systems to improve our statistical modeling processes and computational analysis Our technologies enable the d

  20. Slide 20: UltraVector Integrated Suite of Technologies

    UltraVector® Integrated Suite of Technologies Cell Systems Informatics Enables the rapid, rational design and construction of Better DNA® containing integrated biofunctional systems Inducible Gene Systems Genome Engineering Cell Processing Proprietary Cell Delivery DNA/RNA Engineering Protein Engine

  21. Slide 21: Proprietary Operating System for DNA Solutions

    Proprietary Operating System for DNA Solutions Our technology suite comprising our Operating System for DNA Solutions allows us to translate complex DNA into standard components that can be manufactured in an automated format Our proprietary software & design platform enables precise control over fu

  22. Slide 22: Power of the UltraVector Platform

    Standardize Genetic Components to Modular Parts Power of the UltraVector® Platform Utilize Subject Matter Expertise and Software Tools Engineer Biological Programs & Designs Optimize Part Assembly Algorithms for Biofunction Apply Our Scalable DNA Manufacturing Methods Characterize and Catalogue Info

  23. Slide 23: UltraVector Gene Networks Encode for Complex Biosolutions

    UltraVector® Gene Networks Encode for Complex Biosolutions Design Gene Network (> 2 GPs) ORF 5’ MOD What combination of components and gene programs are needed to achieve this outcome? What is the desired biological outcome? Components Dynamic and expansive UltraVector® library of modular components

  24. Slide 24: Controlling Gene Expression with RheoSwitch Technology

    Controlling Gene Expression with RheoSwitch® (RTS®) Technology Our exclusive biologic switch, incorporated into UltraVector® designed vectors, provides the most advanced clinical method to turn gene expression on and off Ability to express proteins and enzymes as well as control level and timing of

  25. Slide 25: Overview of RDEB and Genetically Modified Human Dermal Fibroblasts

    Overview of Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Genetically Modified Human Dermal Fibroblasts (GM-HDF)

  26. Slide 26: High-Level Overview RDEB

    Problem: Patients are not producing collagen VII or producing non-functional collagen VII Cause: A mutation in the COL7A1 gene which encodes for type VII collagen – the main component of anchoring fibrils Symptoms: Blisters and lesions over widespread areas of the body Potential therapy: Genetically

  27. Slide 27: GM-HDF

    GM-HDF A genetically modified (GM) fibroblast upregulated to produce Collagen VII in a controlled manner for localized treatment of RDEB Autologous dermal fibroblast (azficel-T) transfected with a vector containing the gene for COL7A1 Cells will be expanded to clinical populations and administered d

  28. Slide 28: Regulatory

    No clinical trials have been or are currently being conducted with genetically modified human dermal fibroblasts. 10 June 2014: Fibrocell received orphan drug designation from FDA. 4 August 2014: Fibrocell met with FDA for a Pre-IND meeting to discuss the development path for GM-HDF. Regulatory

  29. Slide 29: Chemistry, Manufacturing and Control

    Chemistry, Manufacturing and Control FDA concurrence on draft manufacturing process and specifications for release of Drug Substance and Drug Product GMP manufacture of vector (CoH) In-process testing Skin tissue biopsy collection at a clinic Overnight shipment to Manufacturer Tissue enzymatic diges

  30. Slide 30: Preclinical and Clinical

    Preclinical and Clinical FDA concurrence on preclinical development plan obtained during Pre-IND meeting Materials and cells are being prepared for the conduct of the studies at Stanford University Three evaluations to be conducted in two studies: Multiple doses of GM-HDF in an in vitro organ cultur

  31. Slide 31: Alfred T. Lane, MD, MA, Stanford University

    Alfred T. Lane MD, MA Professor of Dermatology and Pediatrics, Emeritus (Active) Stanford University School of Medicine

  32. Slide 32: Genetically Corrected Fibroblast Therapy for Dystrophic Epidermolysis Bullosa

    Genetically Corrected Fibroblast Therapy for Dystrophic Epidermolysis Bullosa Alfred T. Lane MD, MA Professor of Dermatology and Pediatrics, Emeritus (Active) Stanford University School of Medicine

  33. Slide 33: DEB

    DEB Dystrophic scarring Epidermolysis breaking apart of skin Bullosa means blister

  34. Slide 34: RDEB

    RDEB Blisters present soon after birth Diagnosis is made by absence of type VII collagen in the upper most dermis at junction of epidermis Many years of painful, expanding wounds that never heal Death from malnutrition, infection or squamous cell carcinoma (SCC)

  35. Slide 35: Estimated Incidence of RDEB

    Estimated incidence of RDEB is 2-4 infants per million births USA: 4 million annual births leads to 8-16 RDEB infants a year Worldwide: 75 million annual births leads to 150-300 RDEB infants a year

  36. Slide 36: Percent Breakdown of DEB Patients by Age

    Percent Breakdown of DEB Patients by Age 2 Age Group RDEB DDEB >10 41.7% 40.7% 11-20 40.5% 33.9% 21-30 9.8% 8.5% 31-40 4.3% 8.5% 41-50 2.5% 6.8% 51-60 0% 1.7% 61-70 0.61% 0% no DOB 0.61% 0% 92% of RDEB subjects are 30 years old or younger 82.2% of RDEB subjects are 20 years old or younger Provided b

  37. Slide 37: [LOGO]

    [LOGO]

  38. Slide 38: [LOGO]

    [LOGO]

  39. Slide 39: [LOGO]

    [LOGO]

  40. Slide 40: [LOGO]

    [LOGO]

  41. Slide 41: [LOGO]

    [LOGO]

  42. Slide 42: [LOGO]

    [LOGO]

  43. Slide 43: [LOGO]

    [LOGO]

  44. Slide 44: [LOGO]

    [LOGO]

  45. Slide 45: Major Improvements in EB Care

    Major Improvements in EB Care

  46. Slide 46: [LOGO]

    [LOGO]

  47. Slide 47: [LOGO]

    [LOGO]

  48. Slide 48: Current EB Care

    Current EB Care

  49. Slide 49: [LOGO]

    [LOGO]

  50. Slide 50: Current EB Care

    Current EB Care Wound dressings Estimated cost of bandages is $1,000 up to $20,000 a month

  51. Slide 51: Type VII Collagen

    Type VII Collagen Leena Bruckner Tuderman 2010

  52. Slide 52: Anchoring fibrils

    Modified from J. Uitto, “Molecular Therapeutics for Heritable Skin Diseases.” Milestones Cutaneous Biology, November 2012 Anchoring fibrils

  53. Slide 53: Interstitial collagen fibers

    Interstitial collagen fibers Modified from J. Uitto, “Molecular Therapeutics for Heritable Skin Diseases.” Milestones Cutaneous Biology, November 2012

  54. Slide 54: Advantages of Cell Based Therapies for EB

    Advantages of Cell Based Therapies for EB Skin is an easy target Autologous cells have lower risks of rejection Potential lifelong therapy

  55. Slide 55: Stanford Phase Trial

    Stanford Phase 1 Trial 5 adult subjects Expression of type VII collagen at 12 weeks and 6 months Restoration of anchoring fibrils by Electron Microscopy

  56. Slide 56: Keratinocyte Gene Transfer

    skin biopsy grow cells in culture viral transfer and epidermal sheet production Keratinocyte Gene Transfer

  57. Slide 57: Ex Vivo Therapeutic Durability Study

    Ex Vivo Therapeutic Durability Study Experimental Design + Skin BMZ analyses Epidermal Sheet Production Keratinocytes From skin biopsy Viral transfer LZRS-HACol7A1 Mouse Grafting 6-12 days 3-7 days 1 days 12-360 days Human Dermis AlloDerm

  58. Slide 58: Durability of Type VII Collagen Expression in Human Skin

    Durability of Type VII Collagen Expression in Human Skin Anti-HA Pab Anti-Dsg3 Mab Hoechst 33342 10x 10x Anti-HA Pab Anti-Dsg3 Mab Hoechst 33342 4.5 months post grafting 12 months post grafting Epitope-tagged or w.t type VII collagen at dermal-epidermal junction Human origin of the epidermis confirm

  59. Slide 59: Transmission EM analysis of Type VII Collagen Expression

    Transmission EM analysis of Epitope-tagged Type VII Collagen Expression in Human Skin AF - Anchoring fibrils LD - Lamina Densa

  60. Slide 60: LZRSE-Col7A1 Engineered Autologous Epidermal Sheet (LEAES)

    LZRSE-Col7A1 Engineered Autologous Epidermal Sheet (LEAES)

  61. Slide 61: Long Term Safety Issues to be Monitored

    Long Term Safety Issues to be Monitored Skin Cancer Auto-immunity Toxicity

  62. Slide 62: Fibrocell is the scientific leader in autologous fibroblasts

    Fibrocell is the scientific leader in autologous fibroblasts for treating skin and connective tissue diseases

  63. Slide 63: Fibroblasts or Keratinocytes?

    Fibroblasts or Keratinocytes? Fibroblasts can be injected into fingers, hands, mouth, and esophagus Early treatment can avoid scar formation Fibroblast injections are easier than keratinocyte grafting

  64. Slide 64: Fibrocell Science Inc.

    Fibrocell Science Inc. Viral vector inserted into fibroblasts Autologous cells reduce risk of patient rejection Fibroblasts are easily injected into non-wounded or wounded skin

  65. Slide 65: Pre-Clinical Design

    Pre-Clinical Design Skin generated with RDEB keratinocytes grown on genetically corrected RDEB fibroblasts Corrected and generated skin grown on an immune suppressed mouse Document presence of type VII collagen at the basement membrane zone and anchoring fibrils

  66. Slide 66: Successful molecular therapy for EB may lead to development of therapies for other skin

    Successful molecular therapy for EB may lead to development of therapies for other skin diseases as well as diseases affecting other organs

  67. Slide 67: Edward J. Damrose, MD, FACS

    Edward J. Damrose, MD, FACS Associate Professor of Otolaryngology at Stanford University School of Medicine Chief of Laryngology

  68. Slide 68: Phase II Study of Azficel-T for Vocal Fold Scarring

    A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia

  69. Slide 69: Background

    Background Associate Professor of Otolaryngology at Stanford University School of Medicine Chief of Laryngology Specialization in voice disorders 2750 patient visits per year 300 surgical procedures 900 office-based laryngeal procedures

  70. Slide 70: Incidence & Epidemiology

    Incidence & Epidemiology True incidence unknown but grossly underestimated Lifetime risk of a voice disorder is 30% 28 million people with daily voice problem $2.5 billion annual costs for teachers

  71. Slide 71: [LOGO]

    [LOGO]

  72. Slide 72: Vocal Fold Superficial Lamina Propria

    Vocal Fold Superficial Lamina Propria (SLP) Critical for Phonation Fibroblasts Comprised of collagen, elastin, hyaluronic acid

  73. Slide 73: Vocal Fold Sulcus (Scar)

    Vocal Fold Sulcus (Scar)

  74. Slide 74: Etiology

    Etiology Sulcus Vocalis Surgery Radiation therapy Idiopathic Voice abuse Intubation Age

  75. Slide 75: Radiation Therapy

    Radiation Therapy or at. v

  76. Slide 76: Age Related Dysphonia

    Age Related Dysphonia Presbylaryngis – aging of the vocal folds Glottic insufficiency Stereotypic Neurodegnerative disease

  77. Slide 77: Current Treatments - Unilateral

    Current Treatments - Unilateral Voice therapy Surgery Injection (collagen, fat, calcium hydroxylapatite, hyaluronic acid) Implant (PTFE, silastic) Scar disruption

  78. Slide 78: [LOGO]

    [LOGO]

  79. Slide 79: [LOGO]

    [LOGO]

  80. Slide 80: [LOGO]

    [LOGO]

  81. Slide 81: Current Therapy Inadequate

    Current Therapy Inadequate Unable to replace SLP Improve vocal fold closure but not vibration Transient Results unpredictable Highly specialized training

  82. Slide 82: Study Sites and Patients

    Three sites Idiopathic sulcus vocalis or age-related dysphonia Failure of alternative therapies Unilateral or bilateral involvement with poor mucosal vibration 20 patients aggregate

  83. Slide 83: Protocol

    Protocol Post auricular skin biopsy Fibroblasts harvested and prepared Double-blind, placebo controlled Three injections to each affected vocal fold, two weeks apart

  84. Slide 84: Technique Percutaneous or Transoral Injection

    Technique Percutaneous or Transoral Injection

  85. Slide 85: Vocal Fold Injection

    Vocal Fold Injection Office-based procedure Topical and/or local anesthesia Injection into affected side Minimal bleeding Well-tolerated

  86. Slide 86: Efficacy Assessments

    Efficacy Assessments Independent evaluator (speech language pathologist) Primary Mucosal wave grade (videostroboscopy) Voice Handicap Index GRBAS Secondary Visual Analogue Scale Impression of voice quality questionnaire Voice recording for acoustic and perceptual analysis

  87. Slide 87: Key Points

    Key Points Azficel-T could offer a potential cure for scarred, degenerated vocal folds Potential advance in laryngeal surgery with the potential to help millions of people Study design is robust and outcome measurements are thorough and well-conceived May be the most well-designed assessment of a vo

  88. Slide 88: Update: Restrictive Burn Scarring Program

    Update: Restrictive Burn Scarring Program

  89. Slide 89: Update: Restrictive Burn Scarring Program

    Update: Restrictive Burn Scarring Program Enrollment challenges stem from the length of a placebo-controlled study when other non-therapeutic options exist, such as surgery and physical therapy 7 of 21 patients have been enrolled Fibrocell took steps to address the issue: Expanded the number of site

  90. Slide 90: Nathan S. Uebelhoer, DO, FAAD

    CDR (USN Ret) Nathan S. Uebelhoer, DO, FAAD Dermatologic and Laser Surgeon Naval Medical Center San Diego The Aroostook Medical Center

  91. Slide 91: Restrictive Burn Scarring Overview

    40,000 or more yearly hospitalizations for severe burns1 Most cases treated at 127 U.S. burn centers Partial and full thickness (2nd/3rd degree) have potential to form scars Wounds heal by forming scar tissue which shrinks and tightens as it forms The formation of scars can restrict the normal range

  92. Slide 92: Patient Impact

    Iwuagwu, FC, Wilson D, and Bailie F. The use of skin grafts in postburn contracture release: A 10-year review. Plast Reconstr Surg. 1999; 103:1198-1204. Schneider JC, Holavanahali R, Helm P, Goldstein R, Kowalske K. Contractures in burn injury: defining the problem. J Burn Care Res. 2006; 27:508-514

  93. Slide 93: Current Methods of Treatment

    Current Methods of Treatment No FDA approved drug or biologic therapies available Physical and occupational therapy Training for activities of daily living (ADL) Splinting Massage Pressure garments Surgery to release the contracture Flap procedures (Z-plasty) Skin grafting (full or partial thickness

  94. Slide 94: Role of Fibroblasts

    Role of Fibroblasts 5 Human dermal fibroblasts play an essential role in wound healing, migrating to the site of injury Injection into mature burn scars may stimulate a wound healing response Potentially breaks down existing, disorganized extracellular matrix as cells are stimulated to migrate into

  95. Slide 95: Case Study

    Images of right lateral neck showing burn wound pre- and post-treatment Case Study Prior to treatment the patient had severely restricted range of motion of her neck and shoulder and required daily opiate analgesia for her chronic pain. The patient received a total of two 4mL azficel-T treatments in

  96. Slide 96: Case Study

    The same patient subsequently underwent treatment of her upper arm scars. Prior to treatment these scars had been severely disabling, such that she was unable to lift her arm beyond 90° due to pain. By 3 months after a single treatment of 1.5mL of azficel-T each to 2 contracted scar bands on her arm

  97. Slide 97: Case Study

    Case Study Able to lift arm for the first time in 10 years (3 months post-treatment) Case study by Mark Palmer, MD

  98. Slide 98: Restrictive Burn Scarring Phase II

    Double-blind, randomized, placebo-controlled, 21 subjects Trial Initiated; 7 subjects enrolled Multi-center trial: 8 centers 6 month efficacy endpoint Subjects inclusion criteria: Unilateral restrictive burn scars of a jointed area 20-60% restriction in normal range of motion Validated Measurement S

  99. Slide 99: Conclusion

    Conclusion Restrictive burn scars have a major impact on the quality of life for patients Current therapies are limited to physical manipulation, pressure garments and surgery Autologous fibroblasts may provide a non-surgical approach for improvement of range of motion for joints affected by restric

  100. Slide 100: James Byrne, PhD, UCLA

    James Byrne, PhD Assistant Professor, UCLA Consultant, Fibrocell Science, Inc. Founder, Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative

  101. Slide 101: Developing safer personalized cellular therapies using hiPSCs

    PATIENT SKIN BIOPSY (OR OTHER TISSUE) PERSONALIZED CELLULAR THERAPY CULTURE PRIMARY CELLS PATIENT WITH DISEASE, INJURY OR AGE-RELATED TISSUE DEGENERATION NUCLEAR REPROGRAMMING BETA CELLS NEURONS CARDIOMYOCYTES HEMATOPOIETIC CELLS DERIVE HUMAN INDUCED PLURIPOTENT STEM CELLS DIRECTED DIFFERENTIATION T

  102. Slide 102: Part 1. Multiple causes of genetic damage in hiPSCs

    Part 1. There are multiple causes of genetic damage in hiPSCs Fibrocell initiated a sponsored research agreement to investigate if a simple proprietary culture media supplement could: 1) reduce oxidative and replicative stress of hiPSCs and their derivatives, 2) help hiPSCs grow faster & 3) increase

  103. Slide 103: Part 2. Why is this important?

    Part 2. Why is this important? Safety is the number 1 concern of the FDA with regards to personalized hiPSC-based therapeutics. Any technology that significantly increases the safety of personalized hiPSC-based therapeutics would likely become broadly adopted. Current Market for hiPSC-based regenera

  104. Slide 104: Part 3. Does it work?

    ** ** ** ** *** *** *** *** n=3 n=3 n=3 n=3 n=9 n=9 n=9 n=9 n=9 n=9 n=9 n=9 ** = (difference between parental fibroblasts and stem cells without supplement) p < 0.05 *** = (difference between stem cell without supplement and stem cell with supplement) p < 0.05 37% decrease post-reprogramming 47% inc

  105. Slide 105: Stem cells and somatic cells grow faster with supplement

    n = 12 27% increase in doubling rate with supplement ** ** = p<0.05 ** 35% increase in doubling rate with supplement ** = p<0.05 n = 12 ** 13% increase in doubling rate with supplement n = 20 Cell counts of fibroblasts and stem cells grown with and without supplement were taken at 0 and 48 hours pos

  106. Slide 106: Skin cells reprogrammed into stem cells with supplement

    Patient’s skin cells can be reprogrammed into morphologically normal stem cells in the presence of our supplement Day 10: potential stem cell colonies emerge after plating lentiviral-transduced dermal fibroblasts onto mouse feeder cells (no supplement) (with supplement) Day 28: Putative stem cells b

  107. Slide 107: Reprogrammed stem cells express pluripotent markers

    Our supplement reprogrammed stem cells express all of the regular pluripotent stem cell markers OCT-4 SSEA-4 SSEA-3 NANOG Alkaline Phosphatase Tra-1-81 / DAPI Tra-1-60 OCT-4 SSEA-4 SSEA-3 NANOG Alkaline Phosphatase Tra-1-81 / DAPI Tra-1-60 OCT-4 SSEA-4 SSEA-3 NANOG Tra-1-81 / Tra-1-60 Positive Contr

  108. Slide 108: Supplement reduces genetic damage in hiPSCs

    Our supplement reduces the incidence of genetic damage in hiPSCs so, are they safer to use? (checking now) Stem cells without supplement gH2AX/DAPI gH2AX/DAPI Stem cells with supplement ** ** ** = p < 0.05 Stem cell A Stem cell B DNA damage levels are measured via gH2AX expression (green), which is

  109. Slide 109: Supplement allows quick growth of liver cells

    Liver cells with supplement Liver cells with supplement Liver cells without supplement Liver cells without supplement Our supplement allows us to quickly grow liver cells for treating liver disease now checking other cell types

  110. Slide 110: Developing safer personalized cellular therapies using hiPSCs

    CULTURE PRIMARY CELLS PATIENT SKIN BIOPSY (OR OTHER TISSUE) PERSONALIZED CELLULAR THERAPY PATIENT WITH DISEASE, INJURY OR AGE-RELATED TISSUE DEGENERATION NUCLEAR REPROGRAMMING BETA CELLS NEURONS CARDIOMYOCYTES HEMATOPOIETIC CELLS DERIVE HUMAN INDUCED PLURIPOTENT STEM CELLS DIRECTED DIFFERENTIATION T

  111. Slide 111: Question & Answer Session

    g FIBROCELL ——— \ Question & Answer Session

  112. Slide 112: Thank You for Joining Us Today

    Thank You for Joining Us Today

Fibrocell Science — Investor Day (September 2014) on 6ix